Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuti (NQ: IRWD )

8.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17
Open 8.080
Bid (Size) 8.000 (2)
Ask (Size) 8.370 (2)
Prev. Close 8.080
Today's Range 8.080 - 8.080
52wk Range 7.530 - 15.70
Shares Outstanding 156,528,648
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-34.89%
-34.89%
1 Month
-2.88%
-2.88%
3 Month
-40.37%
-40.37%
6 Month
-10.42%
-10.42%
1 Year
-22.46%
-22.46%

More News

Read More
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
A Preview Of Ironwood Pharmaceuticals's Earnings
Via Benzinga
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
Via Talk Markets
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
Via InvestorPlace
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks Mixed, Headed For Monthly Wins
Via Talk Markets
Topics Economy
Exposures Interest Rates
Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?
Via Benzinga
Nasdaq Gains 100 Points Following PCE Data
Via Benzinga
Topics Stocks
Exposures US Equities
PSNY Stock Alert: Polestar Makes Moves With Its Joint Venture
Via InvestorPlace
Ironwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It All
Via Investor's Business Daily
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 4 Health Care Stocks You May Want To Dump In February
Via Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.